Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Sweden

Marie Skłodowska-Curie Action · Running

DIETherapy Targeting Cardiovascular Disease with Microbiota-derived Bioactive Compounds

Coordinator
Goeteborgs Universitet, Sweden
Runs
1 September 2026 to 31 August 2028
Status
Running
EU funding
€236k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101203666

What the project is doing

In the project's own words, from its summary on CORDIS.

Cardiovascular diseases (CVDs) remain the leading cause of mortality worldwide, although advancements in glucose-lowering, weight-reducing, and lipid-lowering therapies. Emerging evidence suggests that the gut microbiome and its metabolites are critically involved in the pathogenesis of various metabolic disorders contributing to CVDs, including obesity and type 2 diabetes, and also play a direct role in CVD development.

Conversely, other reported microbiome-derived compounds appear to be beneficial for the host, exhibiting antioxidant and anti-inflammatory properties. This project aims to explore the therapeutic potential of microbiota-derived polyphenols in modulating the immune system to prevent and treat CVDs. Specifically, this proposal seeks to identify polyphenolic metabolites associated with a reduced risk of atherosclerosis development and to assess their immunomodulatory and protective effects in murine models.

Aim 1 will involve bioinformatic analyses of a large human cohort with comprehensive microbiome and metabolome data to identify polyphenolic candidates associated with a lower risk of atherosclerosis. Aim 2 will explore the capacity of these polyphenols to induce long-term anti-inflammatory phenotypes through epigenetic and transcriptomic reprogramming in human and murine innate immune cells (trained immunity). The therapeutic efficacy of these polyphenols will be further evaluated in murine models of atherosclerosis and chronic inflammation, with a focus on elucidating the underlying molecular mechanisms.

The methodologies employed will include advanced bioinformatics, in vitro immune cell assays, and in vivo murine studies, including microbiota and metabolome profiling. This interdisciplinary approach, combining human clinical data with mechanistic studies in mice, is expected to provide new insights into the role of microbiota-derived polyphenols in CVD prevention and treatment, potentially leading to novel therapeutic interventions.

Topics

Who is involved

OrganisationCityCountryRole
Goeteborgs UniversitetGoeteborgSwedenCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI